Author Uhl, W.
-
2003 | Journal Article
Technical performance and diagnostic utility of the new Elecsys (R) neuron-specific enolase enzyme immunoassay
Muley, T.; Ebert, W.; Stieber, P.; Raith, H.; Holdenrieder, S.; Nagel, D. & Fürst, H. et al. (2003)
Clinical Chemistry and Laboratory Medicine (CCLM), 41(1) pp. 95-103. DOI: https://doi.org/10.1515/CCLM.2003.017
Details DOI PMID PMC WoS
-
2019 | Journal Article |
Consensus in determining the resectability of locally progressed pancreatic ductal adenocarcinoma – results of the Conko-007 multicenter trial
Wittel, U. A.; Lubgan, D.; Ghadimi, M. ; Belyaev, O.; Uhl, W.; Bechstein, W. O. & Grützmann, R. et al. (2019)
BMC Cancer, 19(1). DOI: https://doi.org/10.1186/s12885-019-6148-5
Details DOI
-
2020 | Journal Article |
R0 resection following chemo (radio)therapy improves survival of primary inoperable pancreatic cancer patients. Interim results of the German randomized CONKO-007± trial
Fietkau, R.; Grützmann, R.; Wittel, U. A.; Croner, R. S.; Jacobasch, L.; Neumann, U. P. & Reinacher-Schick, A. et al. (2020)
Strahlentherapie und Onkologie, 197(1) pp. 8-18. DOI: https://doi.org/10.1007/s00066-020-01680-2
Details DOI
-
2021 | Journal Article
LBA56 Perioperative or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer: Results of the NEONAX trial, a randomized phase II AIO study
Seufferlein, T.; Uhl, W.; Algül, H.; Friess, H.; Kornmann, M.; König, A. & Ghadimi, M. et al. (2021)
Annals of Oncology, 32 pp. S1333. DOI: https://doi.org/10.1016/j.annonc.2021.08.2136
Details DOI
-
2022 | Journal Article
Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX) - a randomized phase II trial of the AIO pancreatic cancer group
Seufferlein, T.; Uhl, W.; Kornmann, M.; Algül, H.; Friess, H.; König, A. & Ghadimi, M. et al. (2022)
Annals of Oncology,. DOI: https://doi.org/10.1016/j.annonc.2022.09.161
Details DOI